retatrutide peptide trial Retatrutide: A Promising Option for

Indications (Market Use Context)

This phenomenon is further illustrated by results from a randomized, open-label mechanistic trial in patients with T2DM, which demonstrated that lixisenatide, with a half-life of 2 4 hours, had a significantly greater effect than liraglutide in delaying in gastric emptying and curtailing postprandial glucose excursions following a standardized solid breakfast (156)

When you're losing significant weight and adjusting medications, having local medical support matters

However, participants had not yet reached a weight plateau by 48 weeks, hinting at even greater potential with longer treatment